Skip to Main Content

Paper Details

Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study.
Clinical Gastroenterology and Hepatology
26
2022
CD, Cancer, Crohn's disease, IBD, Inflammatory Bowel Disease, Malignancy, Patients, TNF, Tumor Necrosis Factor, UC, VDZ, Vedolizumab, anti-TNF, cancer, cancers, inflammatory bowel diseases, malignancy, patients, person, primary cancer, solid tumors, tumor necrosis factor, ulcerative colitis
Author NameAffiliation
Ashwin N AnanthakrishnanMassachusetts General Hospital and Harvard Medical School
  • 1 - 1

Datasets

Release 1.2